Sandoz has settled US patent-litigation proceedings with Bausch Health’s Salix affiliate over the generics company’s application for a rival to the originator’s Xifaxan (rifaximin) 550mg tablets, obtaining a guaranteed market entry date that matches that afforded previously to Teva’s Actavis.
Having been sued by Salix and patent licensor AlfaSigma in October 2019, for alleged infringement of 14 of Xifaxan’s 23...






